ClinicalTrials.gg
TerminatedNCT07553299Updated Oct 13, 2026

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

A Phase 2 interventional study of VRB-101 and Placebo in Obesity, Overweight and Weight Maintenance, sponsored by Verdiva Bio Dev Limited. Terminated at 20 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Verdiva Bio Dev Limited · Phase 2, Interventional, and Treatment

Why this study was terminated
The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings.
Updated Oct 13, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.

Read the detailed description

This is a randomized, double-blind, placebo-controlled study to evaluate the efficacy of oral ecnoglutide (VRB-101) in participants with a history of obesity or overweight who have achieved weight reduction after 6 months of treatment with injectable semaglutide or tirzepatide. The study comprises three active arms and one placebo arm.

The study will include a Screening Period of approximately 4 weeks, followed by a 16-week Treatment Period and a 4-week Safety Follow-up Period prior to the end of the study.

02

Conditions studied

  • Obesity
  • Overweight
  • Weight Maintenance

Keywords

  • Weight reduction
  • Glucagon-like peptide-1 (GLP-1)
  • Chronic Weight Management
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

This study's enrollment of 8 is below the median of 67 across 9,016 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Verdiva Bio Dev Limited is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a history of of ≥30 kg/m2 OR ≥27 kg/m2 and \<30 kg/m2 with at least 1 weight-related comorbidity at the time of initiation of subcutaneous (SC) semaglutide and/or tirzepatide treatment.
  • Documented history of having obesity or overweight with weight-related comorbidities per medical records at the time of initiation of SC semaglutide and/or tirzepatide treatment.
  • History of treatment with weekly SC semaglutide and/or tirzepatide for a minimum of 6 months prior to Screening.
  • Documented weight reduction of ≥10% in 6 months and no weight regain.
  • Participants of (POCBP) must be non-pregnant and non-lactating and must agree to use study-specified methods.

Exclusion criteria

Exclusion Criteria:

  • Current or past diagnosis of diabetes mellitus [type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM), or other forms of diabetes mellitus]. A participant with a history of gestational diabetes may be included in the study if the participant has \<6.5% at Screening and is not on medication to lower glucose.
  • At least 1 laboratory value suggestive of diabetes during screening, including 1 or more of HbA1c ≥6.5% (48 mmol/mol) or random glucose ≥200 mg/dL (11.1 mmol/L).
  • Diagnosed with obesity due to endocrinologic disorders (for example, Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (for example, melanocortin 4 receptor deficiency or Prader-Willi syndrome)
  • History of gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction).
  • Evidence of uncontrolled hypothyroidism or hyperthyroidism based on an abnormal thyroid-stimulating hormone (TSH).
  • Personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma.
  • Evidence of a significant, uncontrolled endocrine abnormality (for example, thyrotoxicosis or adrenal crises)
  • Renal impairment measured as \<30 mL/min/1.73 m2
  • History of acute or chronic pancreatitis or clinically significant gallbladder disease.
  • Triglycerides >500 mg/dL (5.7 mmol/L) at Screening.
  • Poorly controlled hypertension or an elevated resting pulse rate (>100 bpm).
  • Current treatment with or history of treatment with (within 3 months prior to Screening) medications that may cause significant weight gain.
  • Prior or planned surgical treatment for obesity, plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to Screening.
  • Known to any of the study drug ingredients.
  • Are pregnant or lactating at Screening or planning to become pregnant (self or partner) at any time during the study and for at least 60 days after completion of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    VRB-101 (Active Arm 1)

    Participants will receive VRB-101 once every week.

    Drug: VRB-101

  • Experimental
    VRB-101 (Active Arm 2)

    Participants will receive VRB-101 once every week.

    Drug: VRB-101

  • Experimental
    VRB-101 (Active Arm 3)

    Participants will receive VRB-101 once every week.

    Drug: VRB-101

  • Placebo comparator
    Placebo

    Participants will receive matching placebo to VRB-101 once every week.

    Drug: Placebo

Interventions

  • DrugVRB-101

    VRB-101 tablets will be administered orally.

    Also known as: Oral ecnoglutide

  • DrugPlacebo

    Placebo tablets will be administered orally.

06

What researchers measure

Primary outcomes

  1. To identify the dose of VRB-101 for weight maintenance

    Time frame: Baseline to End of Treatment (Week 17)

Secondary outcomes

  1. Percent change in body weight from baseline

    Time frame: Baseline to End of Treatment (Week 17)

  2. Absolute change in body weight from baseline

    Time frame: Baseline to End of Treatment (Week 17)

  3. Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs) and Adverse events of special interest (AESIs)

    Time frame: Baseline to Week 24

  4. Change in blood pressure from baseline

    Time frame: Baseline to End of Treatment (Week 17)

  5. Change in Columbia-Suicide Severity Rating Scale (C-SSRS) from baseline

    The C-SSRS systematically assesses suicidal ideation and behavior using yes/no questions, ordinal severity ratings (0-5), and intensity subscales. Results at End of Study will be compared to Baseline.

    Time frame: Baseline to End of Treatment (Week 17)

07

Study locations

20 sites
  • Clinical Study Site 202
    Cullman, Alabama 35055, United States
  • Clinical Study Site 203
    Phoenix, Arizona 85028, United States
  • Clinical Study Site 212
    Tempe, Arizona 85281, United States
  • Clinical Study Site 201
    Little Rock, Arkansas 72205, United States
  • Clinical Study Site 214
    Santa Maria, California 93454, United States
  • Clinical Study Site 216
    Stamford, Connecticut 06905, United States
  • Clinical Study Site 204
    Bradenton, Florida 34209, United States
  • Clinical Study Site 221
    Orange City, Florida 32763, United States
  • Clinical Study Site 215
    St. Petersburg, Florida 33704, United States
  • Clinical Study Site 219
    Niles, Illinois 60714, United States
  • Clinical Study Site 213
    El Dorado, Kansas 67042, United States
  • Clinical Study Site 210
    Petal, Mississippi 39465, United States
  • Clinical Study Site 205
    Buffalo, New York 14217, United States
  • Clinical Study Site 206
    Lenoir, North Carolina 28645, United States
  • Clinical Study Site 220
    Oklahoma City, Oklahoma 73111, United States
  • Clinical Study Site 209
    Jackson, Tennessee 38305, United States
  • Clinical Study Site 217
    Houston, Texas 77008, United States
  • Clinical Study Site 211
    Houston, Texas 77040, United States
  • Clinical Study Site 218
    Irving, Texas 75063, United States
  • Clinical Study Site 207
    Richmond, Virginia 23226, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2026 to primary completion in Sep 2026, 2 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Nov 2026 → Sep 2026 and completion Dec 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 28, 2026
StartActual
Jun 12, 2026
Primary completionActual
Sep 11, 2026was Nov 2026
CompletionActual
Sep 11, 2026was Dec 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings.
changed Oct 13, 2026
Primary completion
Nov 30, 2026→Sep 11, 2026 (actual)
Oct 13, 2026
Study completion
Dec 31, 2026→Sep 11, 2026 (actual)
Oct 13, 2026
Enrollment
120 (estimated)→8 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Terminated
    Why stopped The Study Sponsor made a business decision not to continue the study. The decision was not based on safety findings.
    Primary completion Nov 30, 2026→Sep 11, 2026 (now actual)
    Study completion Dec 31, 2026→Sep 11, 2026 (now actual)
    Enrollment 120 (estimated)→8 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07553299
Lead sponsor
Verdiva Bio Dev Limited
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
Jun 12, 2026
Primary completion
Sep 11, 2026
Completion
Sep 11, 2026
Last update
Oct 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion